1. What Is the Neuropathic Pain Market?
The Neuropathic Pain Market covers the medicines used to treat the pain that arises from the damage or disease of the somatosensory nervous system. The conditions include the diabetic peripheral neuropathy, the postherpetic neuralgia, the trigeminal neuralgia, and the chemotherapy-induced peripheral neuropathy. The central pain syndromes that the spinal cord injury, the multiple sclerosis, and the stroke create in the central nervous system are also included. The first-line treatments include the gabapentinoids pregabalin and gabapentin, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine, and the tricyclic antidepressants. The clinical guidelines recommend these before the opioid analgesics that the long-term efficacy, the tolerance, and the dependence concerns limit to the short-term or the pain unresponsive to non-opioid treatments. Neuropathic pain drug development has been characterised by the high rate of clinical trial failure that the heterogeneous patient population and the high placebo response rate in the pain trials create. The inadequate patient selection includes the responder and non-responder patients without the pharmacogenomic or biomarker stratification. The stratification would identify the patient population most likely to respond to the specific mechanism being tested. The neuropathic pain market is advancing with the selective sodium channel Nav1.7 and Nav1.8 inhibitors that pharmaceutical developers are advancing for the peripheral neuropathic pain. The sodium channel subtype selectivity provides the pain signal blockade without the CNS side effects that the non-selective sodium channel blockers including carbamazepine and lidocaine create.
2. Neuropathic Pain Market Size & Forecast
3. Emerging Technologies
- Gabapentinoid mechanism of action on the voltage-gated calcium channel alpha-2-delta subunit reduces the calcium influx and the neurotransmitter release at the hyperexcited synapses in the spinal dorsal horn that central sensitisation creates. The mechanism provides the rationale for the efficacy in the neuropathic pain syndromes. The central sensitisation amplifies the peripheral nociceptive input to the pain level that exceeds the actual tissue damage that the original injury created.
- Nav1.7 sodium channel selective inhibitor VX-548 Vertex Pharmaceuticals demonstrated 30 percent pain reduction versus placebo in the acute pain Phase IIb trial and the ongoing neuropathic pain clinical programme. The proof-of-concept supports the peripherally restricted sodium channel subtype inhibitor that blocks the pain signal at the peripheral nociceptor. The non-selective sodium channel blockers require the CNS penetration for the pain relief that they achieve with the accompanying drowsiness and the cognitive impairment.
- Capsaicin high-concentration 8 percent topical patch Qutenza delivers the defunctionalisation of the TRPV1-expressing cutaneous nociceptors through the localised application of the concentrated capsaicin. The application depletes the substance P from the peripheral nociceptor terminals. The peripheral pain relief for the postherpetic neuralgia and the HIV-associated neuropathy proceeds without the systemic adverse effects that the systemic agent creates.
- Spinal cord stimulation uses the conventional tonic, the high-frequency 10 kHz, and the burst stimulation waveforms. The Nevro HF10, the Abbott Dorsal Root Ganglion stimulation, and the Boston Scientific Spectra deliver the waveforms to the dorsal column and the DRG. The neuromodulation treats the refractory chronic neuropathic pain. The treatment-refractory patient who has failed the medication options benefits from the neuromodulation approach that the pharmacological treatment cannot adequately manage.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Chronic Pain Market.
4. Key Market Opportunity
Meaningful upside in the Neuropathic Pain market involves selective Nav1.8 sodium channel inhibitor approval and adoption, where suzetrigine and other selective sodium channel inhibitors aim to provide effective pain relief without opioid dependency risk or gabapentinoid central nervous system side effects. Companies advancing approved selective Nav inhibitors capture demand for non-opioid pain alternatives. A parallel growth driver is driven by expanding capsaicin patch use across more neuropathic pain conditions. As Nav inhibitor approvals mature and capsaicin patch indications expand, the addressable opportunity is growing from gabapentinoid-dominant treatment toward novel mechanism non-opioid neuropathic pain options.
5. Top Companies in the Neuropathic Pain Market
The following organisations hold leading positions in the Neuropathic Pain Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Pfizer
- Eli Lilly
- Sun Pharma
- Cipla
- Sanofi
- Teva Pharmaceutical
- Viatris
- Vertex Pharmaceuticals
- Tris Pharma
6. Market Segmentation
The Neuropathic Pain Market is analysed across 3 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | GabapentinoidSNRITricyclicSodium Channel BlockerTopical Capsaicin |
| By Indication | DPNPHNChemotherapy-InducedSciatica |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Neuropathic Pain Market trajectory over the forecast period:
Nav1.7 Selective Sodium Channel Inhibitor VX-548 Demonstrating 30 Percent Pain Reduction in Acute Pain Phase IIb Has Established Proof-of-Concept for the Peripherally Restricted Subtype-Selective Inhibitor That Blocks Pain Signal Without the CNS Penetration That Creates Non-Selective Sodium Channel Blocker Side Effects.Vertex Pharmaceuticals's suzetrigine Journavx demonstrated superiority over placebo in two Phase 3 acute pain trials including VALOR with 48% of patients achieving 50-plus percent pain reduction versus 34% for placebo, earning FDA approval in January 2025 as the first non-opioid, non-controlled-substance acute pain treatment with a novel mechanism. The NaV1.8 selectivity achieved by suzetrigine's unique binding site different from the pore-blocking site used by local anaesthetics enables peripheral sensory neuron sodium channel inhibition without cardiac, CNS, or motor effects that limit less selective sodium channel blockers. The commercial opportunity for suzetrigine extends beyond the moderate-to-severe acute pain indication into chronic neuropathic pain conditions including painful diabetic neuropathy, small-fibre neuropathy, and lumbosacral radiculopathy where current treatment options including gabapentinoids and duloxetine provide inadequate relief in the majority of patients.
Capsaicin 8 Percent Qutenza Topical Patch TRPV1 Nociceptor Defunctionalisation Delivering Local Peripheral Relief for Postherpetic Neuralgia Without Systemic Adverse Effects Has Provided the Localised Peripheral Neuropathic Pain Treatment That Systemic Agents Cannot Match.Pfizer and Eli Lilly's tanezumab nerve growth factor antibody achieved the highest pain relief ever demonstrated in pharmacological osteoarthritis trials with 50-plus percent reduction in pain intensity compared to naproxen controls, but a 3-4% rate of quickly progressing osteoarthritis requiring joint replacement in the Phase 3 trials created an unfavourable benefit-risk assessment that led FDA to reject the NDA for moderate-to-severe OA pain. The NGF pathway in joint pain is sufficiently important that the unmet need remains despite the tanezumab setback, and smaller biotech companies are pursuing selective TrkA inhibitors with alternative structural designs aimed at maintaining pain relief while reducing the joint destruction risk associated with complete NGF blockade. The tanezumab experience illustrates the difficulty of achieving approval in chronic pain with high-efficacy but mechanistically concerning adverse effects in a regulatory environment where long-term OA joint safety data is weighed against even substantial analgesic benefit.
High-Frequency 10 kHz Spinal Cord Stimulation HF10 and DRG Stimulation Providing Neuromodulation for Refractory Chronic Neuropathic Pain That Pharmacological Treatment Cannot Adequately Manage Has Established the Interventional Pain Management Role Beyond the Medication-Responsive Patient.Spravato's nasal esketamine for treatment-resistant depression has validated FDA approval for a ketamine-class product, and analogous nasal formulations of racemic ketamine for neuropathic pain refractory to standard therapy are being developed by speciality pharmacies and pharmaceutical companies including Ketamine Bioscience and Zelira Therapeutics. Topical ketamine-amitriptyline-baclofen compounded creams are prescribed in approximately 15% of neuropathic pain patients receiving ketamine therapy, providing localised analgesic effects for conditions including complex regional pain syndrome, post-herpetic neuralgia, and chemotherapy-induced peripheral neuropathy where topical application reduces systemic dissociative effects. The regulatory pathway for ketamine-class analgesic formulations requires navigating controlled-substance scheduling that restricts prescribing to licensed facilities or practitioners and creates access inequities that are particularly challenging for patients in rural areas without proximity to ketamine infusion clinics.
For related market intelligence, see the Pharmaceutical Market.
8. Segmental Analysis
By drug class, the gabapentinoid segment dominated the Neuropathic Pain Market in 2025, as genericised pregabalin and gabapentin from Pfizer and multiple manufacturers anchored first-line treatment across diabetic neuropathy and postherpetic neuralgia, generating the broadest prescription base in the indication.
By indication, the diabetic peripheral neuropathy segment is projected to register the highest growth rate through 2034, as Vertex Pharmaceuticals's selective sodium-channel inhibitors and emerging non-opioid mechanisms address the large and growing diabetic population seeking alternatives to existing therapy.
9. Regional Analysis
Regional demand patterns across the Neuropathic Pain Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Neuropathic Pain Market in 2025, accounting for approximately 47% of global revenue, due to US prescribing volume for gabapentin, pregabalin, and duloxetine and the concentration of Nav inhibitor and novel mechanism clinical development. Moreover, capsaicin 8 percent patch adoption is most advanced in US pain management settings. In addition, suzetrigine and Nav inhibitor clinical adoption is centred in North America. Regional dominance is attributed to this combination of prescribing scale and novel mechanism development.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Neuropathic Pain Market through 2034, driven by the large diabetic peripheral neuropathy patient population in China and India and expanding neuropathic pain diagnosis and prescribing. The region is also witnessing gabapentinoid prescribing growing. Moreover, novel mechanism adoption is expanding with clinical trial participation. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Neuropathic Pain Market was valued at USD 6.44 Bn in 2025 and is projected to reach USD 10.70 Bn by 2034, growing at a CAGR of 5.8% over the 2026–2034 forecast period.
The Neuropathic Pain Market is projected to grow at a CAGR of 5.8% from 2026 to 2034.
North America dominated the Neuropathic Pain Market in 2025, accounting for approximately 47% of global revenue, due to US prescribing volume for gabapentin, pregabalin, and duloxetine and the concentration of Nav inhibitor and novel mechanism clinical development.
The leading companies in the Neuropathic Pain Market include Pfizer, Eli Lilly, Sun Pharma, Cipla, Sanofi, Teva Pharmaceutical, Viatris, Vertex Pharmaceuticals, Tris Pharma.
Nav1.7 selective sodium channel inhibitor vx-548 demonstrating 30 percent pain reduction in acute pain phase iib has established proof-of-concept for the peripherally restricted subtype-selective inhibitor that blocks pain signal without the cns penetration that creates non-selective sodium channel blocker side effects.
By drug class, the gabapentinoid segment dominated the Neuropathic Pain Market in 2025, as genericised pregabalin and gabapentin from Pfizer and multiple manufacturers anchored first-line treatment across diabetic neuropathy and postherpetic neuralgia, generating the broadest prescription base in the indication.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.